CompletedNCT00531752
Two doses of PF-03654746 for ADHD in adults
About this title
A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
Read the official source — NCT00531752Researchers compared PF-03654746 and placebo, tracking side effects to assess safety in adults with ADHD.
Medication studyAges 18–55United States
Understand this study
What did researchers investigate?
Researchers compared PF-03654746 and placebo, tracking side effects to assess safety in adults with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Lafayette and 6 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateDecember 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 66
- Sponsor
- Pfizer
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00531752
- Official title
Show the full official title
A Phase Iia, Randomized, Double Blind, Placebo Controlled, Three-treatment, Two-period Crossover Study Of The Efficacy And Safety Of Two Doses Of Pf-03654746 In Adults With Attention Deficit Hyperactivity Disorder
Get this study by email
Recruitment & locations
CompletedLafayette · Los Alamitos · Newport Beach
4 more locations
- Chicago
- Cambridge
- New York
- Herndon
Questions about this study
What did researchers investigate?
Researchers compared PF-03654746 and placebo, tracking side effects to assess safety in adults with ADHD.
Who is behind this study?
The study sponsor is Pfizer.
Did this study involve medication?
Yes. The study involved medication, including PF-03654746 and Placebo capsules.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
